Novartis Q2 Oncology Strength Rekindles Buy Thesis, But Valuation and LOE Risks Linger

What happened

Novartis ended Q2 on a high note, with oncology driving remarkably strong performance as Pluvicto sales surged 43.4% year-on-year to $651 million, offsetting Entresto's decline and prompting a rating upgrade to Buy. This momentum reignites the bullish narrative, but the DeepValue Master Report maintains a Potential Sell rating, citing a premium valuation at ~19.5x trailing EPS and visible Entresto loss-of-exclusivity headwinds that could pressure growth. The market already prices robust offset of LOE, leaving little room for error; any stumble in priority brands or margin dilution from $12B+ acquisitions would compress multiples. With a base case implied value of $145 and bear case at $120, the current $144 stock offers a narrow margin of safety and risk-reward skews modestly negative over 6-18 months. Thus, while Q2 delivers near-term cheer, the structural thesis hinges on flawless execution against growing headwinds.

Implication

While Q2 signals strong execution, investors should remain cautious given the rich valuation and looming patent cliffs. The buy thesis rests on sustained double-digit growth from a concentrated portfolio, which may not fully offset Entresto erosion. Position sizing should be careful, and consider trimming into strength.

Thesis delta

The upgrade article suggests renewed bullish sentiment based on Q2 strength, particularly in oncology. This contrasts with the master report's bearish stance, which sees limited upside at current prices. The delta is a short-term positive momentum vs. long-term valuation and LOE risks, with the master report's sell thesis remaining intact unless 2026 guidance shows sustained growth above 5% and margins above 39%.